WuXi Biologics (Cayman) Dirección

Dirección controles de criterios 2/4

El CEO de WuXi Biologics (Cayman) es Chris Chen , nombrado en Jan 2016, tiene una permanencia de 8.83 años. compensación anual total es CN¥96.91M, compuesta por 4.1% salario y 95.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.35% de las acciones de la empresa, por valor de HK$208.62M. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 7.2 años, respectivamente.

Información clave

Chris Chen

Chief Executive Officer (CEO)

CN¥96.9m

Compensación total

Porcentaje del salario del CEO	4.1%
Permanencia del CEO	8.8yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	7.2yrs

Actualizaciones recientes de la dirección

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12

Recent updates

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Chen en comparación con los beneficios de WuXi Biologics (Cayman)?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensación vs. Mercado: La compensación total de Chris($USD13.37M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD887.42K).

Compensación vs. Ingresos: La compensación de Chris ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Chris Chen (51 yo)

8.8yrs

Permanencia

CN¥96,911,000

Compensación

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ge Li	Founder & Chairman	10.8yrs	sin datos	sin datos
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% HK$ 208.6m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% HK$ 8.0m
Ming Tu	CFO & Executive VP	3yrs	sin datos	sin datos
Lihua Yu	COO & Senior VP	less than a year	sin datos	sin datos
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	sin datos	sin datos
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	sin datos	sin datos
Lina Fan	Senior VP & Head of Investor Relations	less than a year	sin datos	sin datos
He Wang	Chief Compliance Officer	2.2yrs	sin datos	sin datos
Li Xiong	VP & Head of Global Human Resources	no data	sin datos	sin datos
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	sin datos	sin datos
Keqiang Shen	Chief Digital Officer	4.8yrs	sin datos	sin datos

2.6yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2269 se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ge Li	Founder & Chairman	10.8yrs	sin datos	sin datos
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% HK$ 208.6m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% HK$ 8.0m
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% HK$ 372.4k
James Larrick	Member of Scientific Advisory Board	6.8yrs	sin datos	sin datos
David D. Ho	Member of Scientific Advisory Board	6.8yrs	sin datos	sin datos
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	sin datos	sin datos
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	sin datos	sin datos
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% HK$ 313.3k
Yanling Cao	Non-Executive Director	8.5yrs	sin datos	sin datos
Yibing Wu	Non-Executive Director	8.5yrs	sin datos	sin datos
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% HK$ 2.9m

7.2yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2269 se considera experimentada (7.2 años de antigüedad promedio).

WuXi Biologics (Cayman) Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

CEO & Executive Director recently sold HK$6.6m worth of stock

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Less than half of directors are independent

Consensus EPS estimates fall by 18%

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 16%

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Consensus revenue estimates fall by 14%

Investor sentiment deteriorates as stock falls 28%

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 20% undervalued

Board Member recently sold HK$25m worth of stock

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023